Related Experiment Video
Updated: May 21, 2026
07:17
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
[Angioimmunoblastic T-cell lymphoma as a very poor-prognosis malignancy--a single centre experience]
S Vokurka1, V Koza, V Vozobulová
1Hematologicko-onkologické oddělení, FN Plzeň. vokurka@fnplzen.cz
Summary
Angioimmunoblastic T-lymphoma (AITL) is a rare cancer with poor prognosis. Early autologous stem cell transplant after chemotherapy offers better outcomes for fit patients, but transplant feasibility is a challenge.
Area of Science:
- Hematology
- Oncology
- T-cell Lymphoma Research
Context:
- Angioimmunoblastic T-lymphoma (AITL) is an aggressive non-Hodgkin lymphoma.
- AITL presents a significant clinical challenge due to its poor prognosis and rarity.
Purpose:
- To analyze treatment outcomes for AITL patients in the Czech Republic.
- To evaluate the efficacy of CHOP-21 chemotherapy and autologous stem cell transplantation (ASCT) in AITL.
Summary:
- Retrospective analysis of 12 newly diagnosed AITL patients (2000-2010).
- CHOP-21 chemotherapy yielded 20% stable disease, 50% partial remission, and 30% complete remission.
- Median event-free survival (EFS) and overall survival (OS) were 8 and 10 months, respectively.
- Complete remission after induction therapy or ASCT significantly improved EFS (43 vs 6 months) and OS (46 vs 6 months).
- ASCT was not feasible in 57% of patients requiring further treatment due to poor performance status or disease progression.
Impact:
- AITL has a high risk of early relapse post-CHOP chemotherapy.
- Early ASCT is crucial for fit patients and should be considered immediately after induction.
- Identifying stem cell donors during induction treatment is vital for timely transplantation.